Prognoix
Singapore
About Prognoix
We believe digital technologies provide the best medium to deliver care for stigmatized illnesses. At Prognoix (pronounced prognoics), we are on a mission to help stigmatized illness patients by delivering science-based clinical care within the comfort and privacy of their homes. We develop low-risk digital and software medical devices that are inherently safe and based on established clinical guidelines. All our products are designed keeping clinicians and patients in mind. Our first product, Melonga, is a software medical device (CE mark class 1) for premature ejaculation, a highly stigmatized illness affecting 30% of all men. Please get in touch with us at [email protected] if you are interested in working with a multicultural team of clinicians and engineers to improve patients' lives.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Estimated revenue: Less than $1M
- Total funding: $448.0K
- Funding stage: Seed
- Last round: Pre-Seed (Feb 2023)
- Website: prognoix.com
- Phone: 3165 0507
Industries & Categories
Health Care, Medical Device, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/prognoix-187783 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.